GSK-444563/014 (Rota-014)

Study of safety, reactogenicity and immunogenicity of two doses of GSK Biologicals' oral live attenuated human rotavirus vaccine co-administered with either oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in healthy infants in South Africa
Rotavirus Vaccine
444563/014 (Rota-014)
Infections, Rotavirus
Phase 2
An annotated case report form is not available for this study. A blank case report form will be provided.
June 2015